Frazier Healthcare Partners
Frazier Healthcare Partners is a healthcare investment firm for pharmaceuticals, healthcare services, &a; medical products.
Business Model:
Revenue: $15M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Frazier Healthcare Partners Information
Geographic Data
Address: 601 Union Street
City: Seattle
State: WA
Zip: 98101
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$6B
Social
Twitter
Linkedin
Crunchbase
Metrics
2,885,569Website Global Rank
5,860Website Monthly Traffic
Twitter Followers
Description
Founded in 1991, Frazier Healthcare Partners is a leading provider of growth capital to healthcare companies. The firm has over $2B under management and has made investments in over 170 healthcare companies, with investment types ranging from company creation and venture capital to growth buyouts and leveraged recapitalizations. Frazier’s experienced team takes an active approach to helping build portfolio companies, leveraging the team’s deep domain expertise and expansive network of healthcare executives, advisors, and industry thought leaders. The firm’s Growth Buyout team invests in profitable companies focusing on healthcare services, pharmaceutical services, medical products, and related sectors. The firm’s Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation.
Contact Phone:
+12066217200
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 10/2015 | Gritstone Bio | Series A | 102M |
| 10/2014 | Imago BioSciences | Series A | 26.5M |
| 11/2020 | Imago BioSciences | Series C | 80M |
| 3/2019 | Imago BioSciences | Series B | 40M |
| 8/2003 | Zonare Medical Systems | Series D | 6.5M |
| 11/2022 | New Amsterdam Pharma | Post-IPO Equity | 0 |
| 3/2019 | Scout Bio | Series B | 20M |
| 5/2003 | Quantum Dot | Series B | 1.5M |
| 4/2010 | Achaogen | Series C | 56M |
| 9/2002 | Alexza Pharmaceuticals | Series A | 0 |
| 12/2007 | PowerVision | Series B | 20M |
| 10/2021 | Radionetics Oncology | Private Equity Round | 30M |
| 11/2021 | Tricida | Post-IPO Equity | 42M |
| 9/2018 | Arcutis Biotherapeutics | Series B | 58M |
| 4/2020 | Aspen Neuroscience | Series A | 0 |
| 11/2011 | Rempex Pharmaceuticals | Series B | 67.5M |
| 6/2016 | Alpine Immune Sciences | Series A | 48M |
| 1/2014 | Ignyta | Debt Financing | 10M |
| 4/2014 | Sierra Oncology | Series D | 0 |
| 1/2012 | Kalidex Pharmaceuticals | Venture Round | 6.5M |
| 1/2020 | Galera Therapeutics | Venture Round | - |
| 6/2008 | EBR Systems | Series C | 35M |
| 6/2010 | Zeltiq Aesthetics | Series D | 25M |
| 5/2007 | Pegasus Biologics | Series C | 20M |
| 6/2003 | QuatRx Pharmaceuticals | Series C | 11.4M |
| 8/2000 | PatientKeeper | Series B | 0 |
| 3/2017 | Vaxcyte | Series B | 60M |
| 7/2021 | Crinetics Pharmaceuticals | Post-IPO Equity | 15M |
| 1/2019 | Sojournix | Series C | 44M |
| 9/2019 | Passage Bio | Series B | 110M |
| 8/2008 | Glaukos | Series D | 35M |
| 1/2012 | Moximed | Venture Round | 1.8M |
| 7/2008 | CVRx | Series E | 0 |
| 5/2007 | Marcadia Biotech | Series A | 15M |
| 9/2021 | Gritstone Bio | Post-IPO Equity | 0 |
| 8/2008 | Calibra Medical | Series B | 35M |
| 3/2020 | Vaxcyte | Series D | 0 |
| 2/2007 | Chimerix | Series D | 23.1M |
| 4/2017 | Cirius Therapeutics | Series A | 0 |
| 6/2005 | Pegasus Biologics | Series B | 10M |
| 7/2020 | MBX Biosciences | Series A | 34.6M |
| 8/2012 | Millendo Therapeutics | Series A | 16M |
| 5/2017 | Iterum Therapeutics | Series B | 65M |
| 1/2020 | Syndax Pharmaceuticals | Post-IPO Debt | 0 |
| 11/2009 | Calypso Medical | Series E | 50M |
| 12/2003 | Avera Pharmaceutical | Series B | 8M |
| 11/2007 | AnaptysBio | Series B | 0 |
| 10/2009 | Threshold Pharmaceuticals | Post-IPO Equity | 35M |
| 8/2018 | Cirius Therapeutics | Series A | 9M |
| 9/2013 | PreCision Dermatology | Debt Financing | 67M |
| 6/2005 | Cierra | Funding Round | 21M |
| 10/2005 | QuatRx Pharmaceuticals | Series D | 17M |
| 5/2020 | Lengo Therapeutics | Series A | 15M |
| 3/2016 | Outpost Medicine | Series A | 41M |
| 1/2010 | VentiRx Pharmaceuticals | Series A | 25M |
| 2/2015 | Laguna Pharmaceuticals | Series B | 30M |
| 12/2021 | Pardes Biosciences | Post-IPO Equity | 0 |
| 10/2003 | Cotherix | Series C | 55M |
| 1/2007 | Calypso Medical | Series D | 42.2M |
| 9/2005 | Amicus Therapeutics | Series C | 55M |
| 10/2019 | Arcutis Biotherapeutics | Series C | 94.5M |
| 9/2020 | Silverback Therapeutics | Series C | 85M |
| 7/2015 | AnaptysBio | Series D | 40M |
| 7/2004 | Zonare Medical Systems | Series E | 34M |
| 8/2009 | Barosense | Series D | 27M |
| 7/2013 | Alcresta | Series B | 10M |
| 6/2016 | Iovance Biotherapeutics | Equity | 100M |
| 1/2009 | Intradigm Corporation | Series B | 0 |
| 3/2015 | Collegium Pharmaceutical | Private Equity Round | 0 |
| 6/2003 | Xoft | Series B | 0 |
| 5/2007 | Portola Pharmaceuticals | Series C | 70M |
| 12/2003 | Portola Pharmaceuticals | Series A | 21M |
| 11/2005 | Portola Pharmaceuticals | Series B | 46M |
| 7/2008 | Portola Pharmaceuticals | Series C | 60.1M |
| 4/2007 | Xoft | Series D | 0 |
| 5/2005 | Xoft | Series C | 0 |
| 4/2003 | Rigel Pharmaceuticals | Post-IPO Equity | 46M |
| 3/2020 | Amunix | Series A | 0 |
| 5/2007 | QuatRx Pharmaceuticals | Series E | 0 |
| 8/2021 | Sonoma BioTherapeutics | Series B | 0 |
| 5/2004 | Amicus Therapeutics | Series B | 31M |
| 3/2004 | Cardiac Dimensions | Series C | 15M |
| 8/2008 | PatientKeeper | Series F | 0 |
| 9/2006 | Amicus Therapeutics | Series D | 60M |
| 2/2019 | Passage Bio | Series A | 115.5M |
| 2/2013 | Glaukos | Series F | 30M |
| 2/2011 | Glaukos | Series E | 0 |
| 1/2005 | Alexza Pharmaceuticals | Series D | 0 |
| 8/2018 | Millendo Therapeutics | Venture Round | 30M |
| 1/2016 | Millendo Therapeutics | Series B | 0 |
| 6/2004 | PatientKeeper | Series D | 0 |
| 2/2008 | Zonare Medical Systems | Equity | 30M |
| 5/2009 | Clovis Oncology | Venture Round | 145M |
| 2/2009 | Cadence Pharmaceuticals | Post-IPO Equity | 86.6M |
| 3/2000 | MEDCHANNEL | Series B | 42M |
| 4/2008 | Stromedix | Series B | 25M |
| 10/2008 | Alnara Pharmaceuticals | Series A | 20M |
| 5/2021 | Hummingbird Bioscience | Series C | 0 |
| 2/2021 | Seraxis | Series C | 40M |
| 9/2017 | Gritstone Bio | Series B | 93M |
| 9/2021 | HilleVax | Equity | 135M |
| 1/2023 | Curve Beam | Funding Round | 0 |
| 1/2007 | Calixa Therapeutics | Funding Round | - |
| 3/2006 | PowerVision | Series A | 2M |
| 1/2020 | Bellus Health | Post-IPO Equity | - |
| 2/2007 | Pivot Medical | Series A | 2M |
| 6/2010 | Incline Therapeutics | Series A | 43M |
| 3/2006 | Zeltiq Aesthetics | Series A | 7.5M |
| 4/2002 | Avera Pharmaceutical | Series A | 20M |
| 8/2018 | Krystal Biotech | Post-IPO Equity | 10M |
| 12/2003 | FlowCardia | Series B | 12M |
| 4/2017 | Arcutis Biotherapeutics | Series A | 13.5M |
| 8/2007 | Tobira Therapeutics | Series A | 31M |
| 3/2009 | Stemgent | Series B | 14M |
| 11/2021 | Silence Therapeutics | Post-IPO Equity | 20M |
| 2/2021 | ESSA Pharma | Post-IPO Equity | 130M |
| 8/2015 | Calibrium | Convertible Note | 1.7M |
| 9/2002 | Glaukos | Series A | 10M |
| 1/2018 | ARMO BioSciences | Venture Round | - |
| 1/2013 | Scilex Holding Company | Venture Round | - |
| 1/2014 | PowerVision | Series D | 0 |
| 1/2006 | Primaeva Medical | Series A | 1.3M |
| 1/2022 | Metagenomi | Series B | 0 |
| 4/2016 | Entasis Therapeutics | Series B | 50M |
| 1/2002 | QuatRx Pharmaceuticals | Series B | 2M |
| 3/2021 | Amunix | Series B | 117M |
| 4/2008 | Nuon Therapeutics | Series B | 27M |
| 11/2021 | SanReno Therapeutics | Funding Round | 0 |
| 5/2019 | Phathom Pharmaceuticals | Private Equity Round | 90M |
| 1/2008 | Ascension Orthopedics | Series D | 21M |
| 1/1996 | Corixa | Venture Round | - |
| 2/2015 | Cidara Therapeutics | Series B | 42M |
| 12/2007 | Cardiac Dimensions | Series D | 0 |
| 11/2018 | Mirum Pharmaceuticals | Series A | 120M |
| 6/2006 | PatientKeeper | Series E | 0 |
| 8/2007 | FlowCardia | Series C | 0 |
| 12/2004 | QuatRx Pharmaceuticals | Series D | 15M |
| 12/2006 | Primaeva Medical | Series B | 7M |
| 5/2011 | Silvergate Pharmaceuticals | Venture Round | 23.6M |
| 12/2014 | Allena Pharmaceuticals | Series B | 0 |
| 1/2005 | PowerVision | Series A | 4.4M |
| 11/2011 | Allena Pharmaceuticals | Series A | 15M |
| 1/2020 | REGENXBIO | Post-IPO Equity | - |
| 4/2012 | Alcresta | Series A | 10M |
| 12/2020 | Rocket Pharmaceuticals | Post-IPO Equity | 299M |
| 6/2017 | Alteon Health | Private Equity Round | - |
| 3/2007 | Stromedix | Series A | 1M |
| 1/1991 | CV Therapeutics | Funding Round | - |
| 12/2007 | Pivot Medical | Series B | 0 |
| 7/2002 | Barosense | Series A | 6.2M |
| 1/1993 | VIVUS | Venture Round | - |
| 3/2016 | Iterum Therapeutics plc | Series A | 40M |
| 1/2021 | Aclaris Therapeutics | Post-IPO Equity | - |
| 3/2020 | Molecular Templates | Post-IPO Debt | 45M |
| 8/2021 | Immunovant | Corporate Round | 200M |
| 3/2007 | Calistoga Pharmaceuticals | Series A | 21M |
| 12/2015 | Allena Pharmaceuticals | Series C | 0 |
| 3/2010 | Nuon Therapeutics | Venture Round | 6M |
| 11/2007 | Zonare Medical Systems | Series G | 30M |
| 6/2020 | Lassen Therapeutics | Series A | 31M |
| 8/2010 | Nuon Therapeutics | Venture Round | 10M |
| 11/2006 | Bariatric Partners | Series B | 0 |
| 1/2000 | ZymoGenetics | Funding Round | - |
| 6/2005 | Pegasus Biologics | Series B | 10M |
| 8/2013 | Semnur Pharmaceuticals | Venture Round | 6M |
| 5/2007 | Arete Therapeutics | Series A | 35M |
| 9/2020 | Trillium Therapeutics | Post-IPO Equity | 25M |
| 6/2010 | Calistoga Pharmaceuticals | Series C | 40M |
| 12/2009 | EBR Systems | Venture Round | 15M |
| 5/2016 | Aptinyx | Series A | 0 |
| 10/2020 | Scholar Rock | Post-IPO Debt | 50M |
| 2/2012 | Collegium Pharmaceutical | Venture Round | 22.5M |
| 8/2005 | Cerexa Inc. | Series A | 0 |
| 1/2006 | Xoft | Series C | 0 |
| 7/2010 | BARRX Medical | Series D | 15M |
| 9/2021 | Alpine Immune Sciences | Private Placement | 91M |
| 1/2019 | Alpine Immune Sciences | Post-IPO Equity | 25M |
| 1/2020 | Tarsus Pharmaceuticals | Series B | 60M |
| 12/2004 | Barosense | Series B | 6.2M |
| 3/2016 | Zavante Therapeutics | Series A | 45M |
| 1/2021 | Avadel Pharmaceuticals | Post-IPO Equity | - |
| 3/2013 | AcertaPharma | Series A | 60M |
| 4/2020 | Dascena | Series B | 50M |
| 2/2000 | PatientKeeper | Series A | 8.6M |
| 10/2005 | EBR Systems | Series B | 21M |
| 1/1998 | Array BioPharma | Venture Round | - |
| 7/2006 | BARRX Medical | Series C | 27.8M |
| 6/2014 | Cidara Therapeutics | Series A | 32M |
| 6/2003 | QuatRx Pharmaceuticals | Series C | 14M |
| 2/2011 | Chimerix | Series F | 45M |
| 1/2020 | Epizyme | Post-IPO Equity | - |
| 1/2017 | The CORE Institute | Private Equity Round | - |
| 2/2000 | Xenoport | Series A | 15.9M |
| 3/2007 | VentiRx Pharmaceuticals | Series A | 26.6M |
| 3/2013 | Achaogen | Series D | 18.9M |
| 8/2004 | Avera Pharmaceutical | Series C | 0 |
| 10/2021 | Scout Bio | Series B | 0 |
| 1/2000 | Simpata Inc | Series B | 20M |
| 7/2008 | Collegium Pharmaceutical | Series D | 0 |
| 1/1991 | Tularik | Funding Round | - |
| 5/2007 | Pegasus Biologics | Series C | 20M |
| 2/2019 | Recida Therapeutics | Series A | 8.5M |
| 1/1996 | ViroPharma | Funding Round | - |
| 7/2011 | PowerVision | Series C | 24M |
| 10/2007 | Zeltiq Aesthetics | Series B | 20.3M |
| 9/2010 | Tobira Therapeutics | Series B | 31M |
| 1/2020 | IVERIC bio | Post-IPO Equity | - |
| 5/2007 | CVRx | Series D | 65M |
| 9/2000 | Zonare Medical Systems | Series B | 9.5M |
| 5/2009 | Calistoga Pharmaceuticals | Series B | 30M |
| 1/2005 | Calypso Medical | Series C | 6.8M |
| 12/2007 | Barosense | Series C | 11.2M |
| 12/2020 | Sutro Biopharma | Post-IPO Equity | 144.9M |
| 11/2009 | Calibra Medical | Venture Round | 1.4M |
| 11/2017 | Outpost Medicine, LLC | Series A | 20M |
| 10/2007 | Altiris Therapeutics | Series B | 0 |
| 6/2004 | EBR Systems | Series A | 5.2M |
| 2/2009 | Primaeva Medical | Series C | 6M |
| 1/1997 | OraPharma Inc. (acquired by JNJ) | Venture Round | - |
| 4/2001 | Fast Track | Series C | 0 |
| 11/2006 | Intradigm Corporation | Series A | 16M |
| 9/2014 | VentiRx Pharmaceuticals | Series B | 50.6M |
| 7/2004 | Trubion Pharmaceuticals | Series B | 32M |
| 2/2015 | Merganser Biotech | Series A | 28M |
| 11/2017 | Mavupharma | Series A | 0 |
| 12/2017 | Aptinyx | Series B | 70M |
| 11/2020 | Inipharm | Series A | 0 |
| 1/2022 | Metagenomi | Series B | 0 |
| 12/2021 | Pardes Biosciences | Post-IPO Equity | 0 |
| 11/2021 | SanReno Therapeutics | Funding Round | 0 |
| 11/2021 | Tricida | Post-IPO Equity | 0 |
| 11/2021 | Silence Therapeutics | Post-IPO Equity | 0 |
| 10/2021 | Scout Bio | Series B | 0 |
| 10/2021 | Radionetics Oncology | Private Equity Round | 0 |
| 9/2021 | Gritstone Bio | Post-IPO Equity | 0 |
| 9/2021 | Alpine Immune Sciences | Post-IPO Equity | 0 |
| 9/2021 | HilleVax | Venture Round | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
